Navigation Links
Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting

ROCKVILLE, Md., Oct. 22 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will present five posters on the pharmacogenetics of iloperidone at the 57th American Society of Human Genetics (ASHG) annual meeting to be held in San Diego, CA, from October 23 through October 27, 2007. This announcement follows the submission of the NDA filing for iloperidone on September 27, 2007. Iloperidone is an investigational atypical antipsychotic for the treatment of schizophrenia.

The following posters will be presented on Thursday, October 25, 2007, from 4:30 p.m. to 6:30 p.m. PDT, at the San Diego Convention Center.

POSTER 1035 - Whole Genome Association Study Identifies Polymorphisms in

the NPAS3 Gene Associated with Enhanced Response to

Iloperidone Treatment in Patients with Schizophrenia

POSTER 1036 - Pharmacogenetic Study of Iloperidone Treatment in Patients

with Schizophrenia Identifies Markers Associated with


POSTER 1037 - Pharmacogenetic Analysis Shows Differences in Markers

Associated with Response Between Two Atypical

Antipsychotics, Iloperidone and Ziprasidone, in the

Treatment of Patients with Schizophrenia

POSTER 1039 - Whole Genome Association Study Identifies Polymorphisms in

the CERKL Gene Associated with QT Prolongation during

Iloperidone Treatment of Patients with Schizophrenia

POSTER 1040 - Single-Nucleotide Polymorphisms in the CYP2D6 Gene Are

Correlated with Iloperidone Drug Exposure Levels, Affecting

the Degree of QTc Prolongation Associated with Iloperidone


About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company with a focus on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. In addition to iloperidone, Vanda is developing VEC- 162, a compound for the treatment of sleep and mood disorders which is currently in Phase III for sleep disorders. Vanda's third product candidate in clinical development, VSF-173, is currently in a Phase II trial for the treatment of excessive sleepiness. For more on Vanda Pharmaceuticals Inc., please visit

Note Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's report on Form 10-Q for the quarter ended June 30, 2007 (File No. 000-51863). No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Autism Speaks, ... the global movement driven by social media and the generosity of people around the ... encourage their social media networks to give – and share the personal stories behind ...
(Date:11/24/2015)... ... 24, 2015 , ... All her life, Don Peck’s mother wondered if she was a descendant ... have been. After a 25-year search for information, Don and his aunt discovered that ... last name. Turns out, it was Don’s father who was descended from not one, ...
(Date:11/24/2015)... ... ... Dehydration, defined as a loss of body water content, can make people ... heat stroke and death will quickly follow. A normal human body is 70 percent ... and structure requires water to function properly. Kleyne, who believes that medical research will ...
(Date:11/24/2015)... Dublin, CA (PRWEB) , ... November 24, 2015 ... ... Community College District , the only authorized OSHA Training Institute Education Center in ... workplace injuries during the holiday season’s major sales events. As the volume ...
(Date:11/24/2015)... ... November 24, 2015 , ... Add a fresh touch to this year’s ... affordable way to bring long-lasting style and cheer to any space. , Holiday plants ... air and keep on giving all year long. , “Holiday plants make a room ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO) ... of Clinical Services, Education and Human Resources will be presenting ... Oncology Drugs: Health Plan Strategies for a Dynamic Market" on ... Fenrick , a consultant with the Cambridge Advisory Group, where ... The webinar will discuss the rapid growth ...
(Date:11/24/2015)... -- st  Scientific Assembly and Annual Meeting of the ... place in Chicago on Nov-29 th ... st  Scientific Assembly and Annual Meeting of the Radiological Society ... Chicago on Nov-29 th through Dec-4 ... Dynamics will present its revolutionary whole body CZT digital SPECT/CT solution ...
(Date:11/24/2015)... DELRAY BEACH, Fla. , Nov. 24, 2015 ... company , has recently announced the launch of ... --> ... --> --> ... or for during travel and vacation, just got ...
Breaking Medicine Technology: